$IONS 0.53 Developing

Notable posts

• @wallstengine bearish 41 eng

  $ALNY shares are moving higher after the $IONS/$AZN CARDIO-TTRansform Phase 3 trial in ATTR-CM missed its primary endpoint. Wainua/eplontersen did not significantly reduce CV mortality and recurrent CV events vs placebo through Week 140. Ionis said most patients were on stabilizers, with 57% on them at baseline and another 24% starting during the trial The monotherapy subgroup showed a nominally significant benefit, but patients already on stabilizers saw no treatment effect

  view on X →
• @wallstengine bullish 40 eng

  ROCHE KIDNEY DRUG HITS PRIMARY ENDPOINT IN PHASE 3 Roche and $IONS reported positive interim Phase 3 results for sefaxersen in IgA nephropathy, with the drug delivering a statistically significant and clinically meaningful reduction in proteinuria at Week 37. Sefaxersen is a once-monthly, self-administered antisense therapy targeting complement factor B. The safety profile was consistent with prior studies, with no new safety signals. The 459-patient trial will continue through Week 105 to evaluate long-term kidney function. Roche licensed sefaxersen from Ionis, which remains eligible for regulatory and sales milestones plus tiered royalties on net sales. The readout gives Ionis a second positive Phase 3 result in roughly 24 hours, following its FUS-ALS update.

  view on X →
• @TENETTRADEGROUP neutral 23 eng

  Tenet Pre-Market Movers July.09.26 $AEHR $ALNY $AP $SMPL $FCEL $AZZ $ASX $SNDK $GLSI $MARA $MU $BYRN $CBRS $AMAT $CECO $RMBS $BE $AMD $ENPH $IONS $RXT $MDA $AZN $LEVI $RDY $IBM $PLTR $META $PEP @ripster47 | @tenet_research | @TenetCharts https://t.co/koX2y94Wq9

  view on X →